Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS. 
  • Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
  • Collaborations : 
    - Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
    - Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
    - Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 3

ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
  • Project leader : Philippe Aftimos 
  • Collaborations : International clinical study
  • Funding (or) Support : Zenith Epigenetics Ltd.

Project 4

MULTICENTRIC PHASE II SINGLE-ARM STUDY OF NIVOLUMAB IN PATIENTS WITH TYPE B3 THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
  • Project leader : Thierry Berghmans
  • Collaborations : International clinical study
  • Funding (or) Support : EORTC

Project 5

AURA : Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Our team

Head of the Medical Oncology Clinic
Dr L. Buisseret, ad interim

Solid Tumours / New Innovative drugs
Dr Ph. AftimosDr N. Kotecki

Solid and RareTumours 
Dr Ch. Jungels

Breast Oncology 
Dr D. de Valeriola
Dr Ph. AftimosDr A. Gombos
Pr Ch. SotiriouDr E. de Azambuja
Dr M. IgnatiadisDr F. Lebrun 
Dr L. BuisseretPr A. Drowart
Dr D. t’Kint de RoodenbekeDr M. Hanappe

Oncogeriatrics 
Dr L. Dumont (geriatrician)

Cervico-facial Oncology  
Dr Y. LalamiDr S. Luce

Skin Tumour Oncology                 
Pr A. DrowartDr M. Langouo
Dr M. Suppa (dermatologue)

Digestive Oncology / Gastroenterology / Endoscopy
Pr J.L. Van LathemDr A. HendliszDr F. Sclafani,
Prof. A. Demols, Dr L.Mans, Dr A.M. Bucalau
Dr R. Saude Conde

Gynaecological Oncology 
Dr L. PolastroDr F. Lebrun
Dr M. Langouo, Dr M. Hanappe

Thoracic Oncology 
Pr Th. BerghmansDr M. Brandao
Dr Z. Mekinda, Dr A. Goudsmit

Urogenital, Bone and Soft Tissue Oncology
Dr Ch. Jungels (sarcomas)
Dr N. Martínez-Chanza (urogenital tumors)
Dr S. Sideris (urogenital tumors)
Dr M. Panhaleux (urogenital tumors)

Oncological Day Hospital
Dr D. de ValeriolaDr Y. Lalami, Dr L. Polastro

Oncogenetics
Dr D. t’Kint de Roodenbeke

Neuro-oncology
Dr S. Luce

Psychooncology
Pr D. Razavi

Supportive and Palliative Cares / Pain Clinic
Dr I. LibertDr. V. Ligabo

Consultants :    
Pr J. Klastersky (internal medicine/oncology)
Dr Z. El Ali (medical oncology)
Dr J. Kerger (oncologie gynécologique/cutanée)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)

21/06/2024

 Scientific publications

ASO Visual Abstract: Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases.

Authors : El Asmar A, Delcourt M, Kamden L, Khaled C, Bohlok A, Moreau M, Sclafani F, Donckier V, Liberale G
Year : 2023
Journal : Ann Surg Oncol
Volume : 30
Pages : 1872-1873

ESPEN practical guideline: Home parenteral nutrition.

Authors : Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, Lichota M, Mühlebach S, Van Gossum A, Wanten G, Wheatley C, Bischoff SC
Year : 2023
Journal : Clin Nutr
Volume : 42
Pages : 411-430

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.

Authors : Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA
Year : 2023
Journal : JAMA Oncol
Volume : 9
Pages : 29-39

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Authors : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L
Year : 2023
Journal : J Clin Med
Volume : 12

Liquid biopsy accelerates precision medicine.

Authors : Amato O, Aftimos P, Ignatiadis M
Year : 2023
Journal : Ann Oncol